Maven Securities LTD lessened its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Rating) by 93.8% in the third quarter, HoldingsChannel reports. The fund owned 25,000 shares of the biopharmaceutical company’s stock after selling 375,000 shares during the period. Maven Securities LTD’s holdings in Cellectar Biosciences were worth $84,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently modified their holdings of the company. 1900 Wealth Management LLC acquired a new stake in Cellectar Biosciences in the third quarter worth about $40,000. State Street Corp raised its position in shares of Cellectar Biosciences by 4.5% during the 2nd quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 6,800 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Cellectar Biosciences by 31.3% in the 2nd quarter. Renaissance Technologies LLC now owns 166,500 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 39,700 shares during the period. Finally, Worth Venture Partners LLC boosted its holdings in shares of Cellectar Biosciences by 122.8% in the first quarter. Worth Venture Partners LLC now owns 458,245 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 252,570 shares in the last quarter. Institutional investors own 23.23% of the company’s stock.
Analysts Set New Price Targets
CLRB has been the topic of several recent analyst reports. StockNews.com assumed coverage on Cellectar Biosciences in a report on Monday. They set a “sell” rating on the stock. Maxim Group cut their price objective on Cellectar Biosciences to $7.00 in a report on Tuesday, November 15th.
Cellectar Biosciences Price Performance
About Cellectar Biosciences
Cellectar Biosciences, Inc engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
- Get a free copy of the StockNews.com research report on Cellectar Biosciences (CLRB)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Want to see what other hedge funds are holding CLRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Rating).
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.